晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展

doi:10.11904/j.issn.1002-3070.2022.05.013

摘要/Abstract

摘要： 非小细胞肺癌(Non-small cell lung cancer,NSCLC)是肺癌最常见的组织学类型,诊断时多为晚期,病死率较高。免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)的应用显著提高了晚期NSCLC患者的5年生存率,但带来生存获益的同时,也导致免疫相关不良事件(Immune-related adverse events,irAEs)的发生。近年来,irAEs和ICIs临床疗效之间的关联性成为研究的热点。本文就晚期NSCLC中irAEs与免疫治疗疗效的相关性研究进展进行综述。

关键词: 免疫检查点抑制剂, 免疫相关不良反应, 疗效, 非小细胞肺癌

Abstract: Non-small cell lung cancer(NSCLC)is the most common histological type of lung cancer,which is mostly diagnosed at advanced stage and has a high mortality.The application of immune checkpoint inhibitors(ICIs)has significantly improved the 5-year survival rate of patients with advanced NSCLC,but while bringing survival benefits,it also leads to adverse events that are different from traditional treatment regimens,namely immune-related adverse events(irAEs).In recent years,the correlation between irAEs and clinical efficacy of ICIs has become a research hotspot.This article reviews the research progress on the correlation between irAEs and the efficacy of immunotherapy in advanced NSCLC.

Key words: Immune checkpoint inhibitors, Immune-related adverse events, Efficacy, Non-small cell lung cancer

中图分类号:

R730.51

刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.

LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer[J]. Journal of Practical Oncology, 2022, 36(5): 463-467.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.05.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I5/463

参考文献

1 Relli V,Trerotola M,Guerra E,et al.Abandoning the notion of non-small cell lung cancer[J].Trends Mol Med,2019,25(7):585-594.
2 Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J].New Engl J Med,2015,373(17):1627-1639.
3 Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].New Engl J Med,2016,375(19):1823-1833.
4 Glode AE,May MB.Immune checkpoint inhibitors:significant advancements in non-small cell lung cancer treatment[J].Am J Health Syst Pharm,2021,78(9):769-780.
5 Aso M,Toi Y,Sugisaka J,et al.Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer[J].Oncologist,2020,25(3):e536-e544.
6 Cortellini A,Chiari R,Ricciuti B,et al.Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients[J].Clinical Lung Cancer,2019,20(4):237-247.
7 Haratani K,Hayashi H,Chiba Y,et al.Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer[J].JAMA Oncol,2018,4(3):374-378.
8 Hosoya K,Fujimoto D,Morimoto T,et al.Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors[J].Clin Lung Cancer,2020,21(4):e315-e328.
9 Naqash AR,Ricciuti B,Owen DH,et al.Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab:a pooled exploratory analysis from a global cohort[J].Cancer immunol immun,2020,69(7):1177-1187.
10 Ricciuti B,Genova C,De Giglio A,et al.Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab:long-term outcomes from a multi-institutional analysis[J].J Cancer Res Clin Oncol,2019,145(2):479-485.
11 Morimoto K,Yamada T,Takumi C,et al.Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy:a retrospective study[J].Front Oncol,2021,11:630136.
12 Berner F,Bomze D,Diem S,et al.Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer[J].JAMA Oncol,2019,5(7):1043-1047.
13 Zhou C,Chen G,Huang Y,et al.A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic non-squamous non-small cell lung cancer[J].J Thorac Oncol,2019,14(10 Suppl):215-216.
14 Osorio J,Ni A,Chaft J,et al.Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J].Ann Oncol,2017,28(3):583-589.
15 Kim HI,Kim M,Lee SH,et al.Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer[J].Oncoimmunology,2017,7(1):e1375642.
16 Owen DH,Wei L,Bertino EM,et al.Incidence,risk factors,and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer[J].Clin Lung Cancer,2018,19(6):e893-e900.
17 Peiro I,Palmero R,Iglesias P,et al.Thyroid dysfunction induced by nivolumab:searching for disease patterns and outcomes[J].Endocrine,2019,64(3):605-613.
18 Grangeon M,Tomasini P,Chaleat S,et al.Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer[J].Clin Lung Cancer,2019,20(3):201-207.
19 Cheung YM,Wang W,McGregor B,et al.Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors:a systematic review and meta-analysis[J].Cancer Immunol Immunother,2022,71(8):1795-1812.
20 Zhou N,Velez MA,Bachrach B,et al.Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC[J].Lung Cancer,2021,161:34-41.
21 Campredon P,Mouly C,Lusque A,et al.Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer:retrospective study of 105 patients[J].Presse Med,2019,48(4):e199-e207.
22 Ahn BC,Pyo KH,Xin CF,et al.Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice[J].J Cancer Res Clin Oncol,2019,145(6):1613-1623.
23 Fujimoto D,Yoshioka H,Kataoka Y,et al.Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer:a multicenter retrospective cohort study[J].Lung Cancer,2018,119:14-20.
24 Fukihara J,Sakamoto K,Koyama J,et al.Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors[J].Clin Lung Cancer,2019,20(6):442-450.
25 Sugano T,Seike M,Saito Y,et al.Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer[J].Thoracic Cancer,2020,11(4):1052-1060.
26 Ono K,Ono H,Toi Y,et al.Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer[J].Cancer Medicine,2021,10(14):4796-4804.
27 Sato K,Akamatsu H,Murakami E,et al.Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab[J].Lung Cancer,2018,115:71-74.
28 Shankar B,Zhang J,Naqash AR,et al.Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer[J].JAMA Oncol,2020,6(12):1952-1956.
29 Zhang Q,Wang W,Yuan Q,et al.Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer:systematic review and meta-analysis[J].Cancer Chemother Pharmacol,2022,89(1):1-9.
30 Teraoka S,Fujimoto D,Morimoto T,et al.Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab:a prospective cohort study[J].J Thorac Oncol,2017,12(12):1798-1805.
31 Judd J,Zibelman M,Handorf E,et al.Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors[J].Oncologist,2017,22(10):1232-1237.
32 D'arienzo PD,Olsson-Brown AC,Sallam M,et al.Immune-related toxicities in NSCLC:real-world experience from a tertiary cancer center[J].Ann Oncol,2019,30:26-27.
33 Viaud S,Saccheri F,Mignot G,et al.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J].Science,2013,342(6161):971-976.
34 Chaput N,Lepage P,Coutzac C,et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J].Ann Oncol,2017,28(6):1368-1379.
35 Kang J,Bluestone J,Young A.Predicting and preventing immune checkpoint inhibitor toxicity:targeting cytokines[J].Trends Immunol,2021,42(4):293-311.
36 Milano G,Innocenti F,Ciccolini J.The association between adverse events and outcome under checkpoint inhibitors:Where is the deal? [J].Transl oncol,2021,14(1):100952.

[1]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[2]	连晓敏, 马峰, 赵丽霞, 孟玮, 赵丹丹, 赵峻峰. PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析[J]. 实用肿瘤学杂志, 2022, 36(4): 339-345.
[3]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[4]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[5]	梁洁, 王新华, 王健, 夏欢. 非远处转移性甲状腺乳头状癌¹³¹I疗效预测模型的分析[J]. 实用肿瘤学杂志, 2022, 36(3): 220-225.
[6]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[7]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[8]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.
[9]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[10]	刘金爽, 张文静, 黎清炜, 李志伟. 免疫检查点抑制剂的联合治疗在胰腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 49-53.
[11]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[12]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[13]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[14]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[15]	韩淑玲, 姚洋, 刘超, 张艳桥. 肠道微生物影响结直肠癌化疗疗效的研究现状[J]. 实用肿瘤学杂志, 2021, 35(5): 476-479.